- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
Profile
- Financials
Sarepta Therapeutics (SRPT)
Company Profile
| Quarter (USD) | Sep 25 | Jun 25 | Mar 25 | Dec 24 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 626.20 mm | 626.20 mm | 626.20 mm | 626.20 mm | 626.20 mm | 626.20 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 64.68 mm | 21.02 mm | 4.86 mm | 20.39 mm |
| Cash used (since last report) | n/a | n/a | 149.93 mm | 48.71 mm | 11.27 mm | 47.25 mm |
| Cash remaining | n/a | n/a | 476.27 mm | 577.49 mm | 614.93 mm | 578.95 mm |
| Runway (months of cash) | n/a | n/a | 7.4 | 27.5 | 126.5 | 28.4 |
| 13F holders | Current |
|---|---|
| Total holders | 462 |
| Opened positions | 80 |
| Closed positions | 77 |
| Increased positions | 154 |
| Reduced positions | 156 |
| 13F shares | Current |
|---|---|
| Total value | 10.03 tn |
| Total shares | 87.95 mm |
| Total puts | 1.20 mm |
| Total calls | 1.42 mm |
| Total put/call ratio | 0.8 |
| Largest owners | Shares | Value |
|---|---|---|
| BlackRock | 11.19 mm | $1.36 tn |
| Vanguard | 9.09 mm | $1.10 tn |
| Capital International Investors | 8.70 mm | $1.06 tn |
| JHG Janus Henderson | 4.33 mm | $526.20 bn |
| STT State Street | 4.07 mm | $494.85 bn |
| Farallon Capital Management | 2.87 mm | $348.37 bn |
| Avoro Capital Advisors | 2.56 mm | $310.73 bn |
| BK The Bank of New York Mellon Corporation | 2.15 mm | $260.87 bn |
| Wellington Management | 2.07 mm | $251.54 bn |
| JPM JPMorgan Chase & Co. | 2.02 mm | $245.69 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 28 Nov 25 | Cristin Rothfuss | Common Stock | Payment of exercise | Dispose F | No | No | 21.12 | 229 | 4.84 k | 139,756 |
| 17 Nov 25 | Louise Rodino-Klapac | Common Stock | Payment of exercise | Dispose F | No | No | 18.42 | 4,582 | 84.40 k | 224,030 |
| 3 Sep 25 | Louise Rodino-Klapac | Common Stock | Grant | Acquire A | No | No | 0 | 50,000 | 0.00 | 228,612 |
| 3 Sep 25 | Louise Rodino-Klapac | Common Stock | Grant | Acquire A | No | No | 0 | 93,875 | 0.00 | 178,612 |
| 3 Sep 25 | Ryan Ho-Yan Wong | Common Stock | Grant | Acquire A | No | No | 0 | 25,000 | 0.00 | 136,203 |
| 3 Sep 25 | Ryan Ho-Yan Wong | Common Stock | Grant | Acquire A | No | No | 0 | 93,875 | 0.00 | 111,203 |
| 3 Sep 25 | Ian Michael Estepan | Common Stock | Grant | Acquire A | No | No | 0 | 50,000 | 0.00 | 206,487 |
| 3 Sep 25 | Ian Michael Estepan | Common Stock | Grant | Acquire A | No | No | 0 | 93,875 | 0.00 | 156,487 |